Citryll announced that a landmark scientific paper on their NET inhibitor programme has been published in Nature’s Cellular and Molecular Immunology journal.
“This peer reviewed scientific publication forms the foundation of our CIT-013 drug development programme. CIT-013 acts at the level of formation, function and clearance of neutrophil extracellular traps (NETs). The publication describes 5 non-clinical in vivo pharmacological studies, as well as human Rheumatoid Arthritis (RA), Systemic lupus erythematosus (SLE) and mouse in vitro NET formation pharmacology. Besides Citryll’s R&D team in Oss, 3 established academic collaborators in Germany and the US were involved” says CSO Renato Chirivi.

“NETs are shown to play important roles in different human pathologies with high unmet need including autoimmunity and organ damage like in SLE, RA, vasculitis, wound healing and cancer. The new scientific publication captures the data that made us and our investors decide to invest in the CIT-013 programme and start formal development in the spring of 2019”, says CEO Helmuth van Es.

About Citryll: Citryll BV is a private pharmaceutical company based here at Pivot, Park. Citryll is dedicated to the development and commercialization of therapeutics that target the innate immune system in particular NET formation and NETs. Citryll was founded by Helmuth van Es, CEO Citryll who is cofounder of Galapagos, Audion Therapeutics, Antabio and Effecta Pharma), and Renato Chirivi, CSO Citryll and co-inventor of Citryll’s therapeutic antibodies, and ModiQuest B.V., originator of the early tACPA patents, (

The paper can be found at
Contact Citryll: Helmuth van Es +31 (0)6 21 26 05 28